4Filed Aug 4, 8:00 PM ET

Dolby (DLB) SVP John Couling Exercises Options, Sells Shares

$DLB · Dolby Laboratories, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Dolby (DLB) SVP John Couling Exercises Options, Sells Shares

What Happened
John D. Couling, Senior Vice President, Entertainment at Dolby Laboratories, exercised stock options to acquire 7,667 shares of Class A common stock at $45.50 per share (total cost $348,849) on August 3, 2026. On the same day he sold a total of 7,667 shares in two open-market transactions for combined gross proceeds of approximately $460,004 (one block of 783 shares for $46,224 and one block of 6,884 shares for $413,780). The exercised option was part of a grant covering 46,000 shares and was fully vested and exercisable at the time of exercise.

Key Details

  • Transaction date: August 3, 2026; Form 4 filed August 5, 2026 (reporting period Aug 3). This filing appears to be within the typical 2-business-day Form 4 window.
  • Exercise (acquisition): 7,667 shares at $45.50 — $348,849 total.
  • Open-market sales (dispositions): 783 shares at a weighted avg $59.03 ($46,224) and 6,884 shares at a weighted avg $60.11 ($413,780); combined proceeds ≈ $460,004.
  • Shares held after the transactions include 55,114 shares underlying restricted stock units (subject to forfeiture until vesting).
  • Footnotes: Sales occurred in multiple trades — reported weighted averages reflect ranges of $58.89–$59.46 and $59.895–$60.385; the reporting person will provide full trade-by-trade detail upon request.
  • Option detail: The option exercised was part of a 46,000-share grant and was fully vested as of the exercise date.

Context
Couling exercised options and sold the same number of shares on the same day, effectively converting option holdings into cash (a common cashless exercise/sell pattern). Sales by insiders are routine and do not, by themselves, indicate company prospects; purchases are often viewed as a stronger signal of insider bullishness. The filing discloses the exercise and immediate sales transparently and includes the usual footnote detail about price ranges and remaining RSUs.